Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Passwords play a huge role in how you stay safe online. They protect your accounts, devices and money. Still, many people pick logins that criminals can guess in seconds. The latest NordPass report ...

Python has become one of the most popular programming languages out there, particularly for beginners and those new to the hacker/maker world. Unfortunately, while it’s easy to get something up and ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Trump’s latest speech included a confusing word mix-up that quickly caught the internet’s attention. Memes and jokes spread rapidly following the viral moment. Coach John Beam dies after being shot on ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

With Apple’s $20 billion search deal with Google now seemingly safe, investors see AI as one of the company’s other significant perceived threats. But according to CNBC’s Jim Cramer, the court ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...